A Revised Classification of FVIII Concentrates: Rationale and Novel Metrics

Factor VIII (FVIII) replacement remains central to hemophilia A management. Extended half-life (EHL) FVIII concentrates, developed through Fc-fusion or PEGylation, extend terminal half-life and overall exposure (area under the curve, AUC) by approximately 30% compared with standard half-life (SHL) products but remain limited by the von Willebrand factor (VWF)-imposed half-life ceiling. A newly engineered High-Sustained Activity/Ultra-Long FVIII (HSA/UL-FVIII) eliminates VWF binding through multiple structural modifications, achieving a four-fold longer half-life, a six-fold greater AUC than SHL FVIII, and FVIII activity within the non-hemophilia range for several days following once-weekly dosing. Using population pharmacokinetic modeling, we simulated single-dose and steady-state FVIII activity-time profiles in 1,000 virtual patients treated with SHL-, EHL-, or HSA/UL-FVIII. Time spent and area above clinically relevant FVIII thresholds clearly differentiated HSA/UL-FVIII from EHL products. These data support updating FVIII product classification and highlight the value of new PK-based metrics, including time-above-threshold and segmented AUC, in evaluating next-generation FVIII therapies.